Artivion, Inc. (NYSE:AORT – Get Rating) VP Matthew A. Getz sold 6,329 shares of the company’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $15.88, for a total transaction of $100,504.52. Following the completion of the sale, the vice president now owns 30,387 shares in the company, valued at approximately $482,545.56. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Artivion Stock Performance
Shares of AORT stock opened at $15.51 on Friday. The company has a debt-to-equity ratio of 1.11, a current ratio of 5.47 and a quick ratio of 3.74. The firm has a 50-day moving average of $14.28 and a 200-day moving average of $13.27. Artivion, Inc. has a one year low of $9.64 and a one year high of $23.43. The company has a market cap of $634.36 million, a P/E ratio of -21.25 and a beta of 1.39.
Institutional Investors Weigh In On Artivion
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versor Investments LP purchased a new stake in shares of Artivion during the fourth quarter valued at approximately $217,000. UBS Group AG raised its stake in shares of Artivion by 4.4% during the 3rd quarter. UBS Group AG now owns 174,213 shares of the company’s stock worth $2,412,000 after purchasing an additional 7,339 shares during the period. Tudor Investment Corp Et Al boosted its holdings in shares of Artivion by 6.6% in the 3rd quarter. Tudor Investment Corp Et Al now owns 60,544 shares of the company’s stock worth $838,000 after buying an additional 3,727 shares during the last quarter. Invenire Partners LP boosted its holdings in shares of Artivion by 48.1% in the 3rd quarter. Invenire Partners LP now owns 169,414 shares of the company’s stock worth $2,345,000 after buying an additional 55,000 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in Artivion by 52.9% during the fourth quarter. Victory Capital Management Inc. now owns 215,412 shares of the company’s stock valued at $2,611,000 after buying an additional 74,512 shares during the period. Hedge funds and other institutional investors own 87.99% of the company’s stock.
Wall Street Analyst Weigh In
Artivion Company Profile
Artivion, Inc engages in the research and development of solutions which address cardiac and vascular surgeons’ clinical challenges in treating patients with aortic diseases. Its products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants.
Read More
- Get a free copy of the StockNews.com research report on Artivion (AORT)
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
- What is a Mutual Fund? How Does it Work?
- How to Choose a Brokerage Account or Online Broker
- BJ’s Restaurants’ Approaching Buy Point As Earnings Surge 150%
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
